Beyond Bruton's tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody-drug conjugates, CAR T-cells, and novel agents.

"Declarations Ethics approval and consent to participateNot applicable. Consent for publicationThe authors permit the Journal of Hematology and Oncology to publish this work. Competing interestsNE: Research funding from Beigene, Speakers Bureau for Beigene, Incyte, and Novartis, and Honoraria/consulting/ad boards for Merck, ADC Therapeutics, Lilly, and Novartis. The other co-authors do not have no relevant competing interests. Competing interests NE: Research funding from Beigene, Speakers Bureau for Beigene, Incyte, and Novartis, and Honoraria/consulting/ad boards for Merck, ADC Therapeutics, Lilly, and Novartis. The other co-authors do not have no relevant competing interests."

"Funding Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers R01CA282483 (LS), 5KL2TR2734 (LS), IRP (Young investigator award to LS) and ASH Global Research Award; N.J., American Society of Hematology."